This is a randomized, open-label, parallel-design study to be conducted at 75 centers within
the United States. The study will be described to hemodialysis patients. Informed consent
will be obtained and the inclusion/exclusion criteria reviewed. Eligible patients will be
randomized to receive either Renagel or a calcium-based binder.
Starting from the randomization date, mortality data including survival, death date and cause
of death (vital status information) and morbidity data including hospitalization date will be
recorded for all patients. These data will be collected until the end of the study (December
31, 2004, ± 2 weeks). Patients completing or terminating from the study will return to the
phosphate binder prescribed by their usual healthcare provider.